Mark Litton, Athira Pharma CEO

Athi­ra’s al­ter­na­tive Alzheimer’s ap­proach runs in­to a PhII brick wall

Athi­ra Phar­ma re­port­ed an­oth­er set­back Wednes­day as its mid-stage Alzheimer’s study failed, be­com­ing the lat­est biotech to come up short in the dis­ease.

The Seat­tle-area com­pa­ny said the Phase II tri­al com­par­ing its lead can­di­date fos­go­nime­ton, for­mer­ly ATH-1017, against place­bo did not achieve its pri­ma­ry end­point nor a litany of sec­ondary mea­sures. It’s yet an­oth­er chal­lenge for Athi­ra fol­low­ing rev­e­la­tions its for­mer CEO doc­tored some of the com­pa­ny’s foun­da­tion­al re­search in grad school and ac­tivist in­vestor cam­paigns.

Endpoints News

Unlock this article instantly by becoming a free subscriber.

You’ll get access to free articles each month, plus you can customize what newsletters get delivered to your inbox each week, including breaking news.